Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database by Junnila, M. et al.
Suomen Ortopedia ja Traumatologia  Vol. 39 2•2016   SOT  167
Implant survival of the most common cemented total hip 
devices from the Nordic Arthroplasty Register Association data-
base
Junnila M1, Laaksonen I1, Eskelinen A2, 3, Pulkkinen P4, Havelin L5, 6, Furnes O5,6, Fenstad AM5, Pedersen AB7,9, 
Overgaard S8, 9, Kärrholm J10, Garellick G10, Malchau H10, 11, 12, Mäkelä KT1, 3
1. Turku University Hospital, Department of Orthopaedics and Traumatology
2. Coxa Hospital for Joint Replacement
3. Finnish Arthroplasty Register
4. Helsinki University, Department of Public Health
5. Norwegian Arthroplasty Register, Haukeland University Hospital, Department of Orthopaedic Surgery
6. University of Bergen, Bergen, Department of Clinical Medicine
7. Aarhus University Hospital, Competence Centre for Clinical Epidemiology and Biostatistics, North, Depart-
ment of Clinical Epidemiology
8. Odense University Hospital, Department of Orthopaedic Surgery and Traumatology and University of 
Southern Denmark, Institute of Clinical Research
9. Aarhus University Hospital, Danish Hip Arthroplasty Register, Department of Clinical Epidemiology
10. The Swedish Hip Arthroplasty Register, Sahlgrenska University Hospital, Department of Orthopaedics, 
Institute of Surgical Sciences
11. Massachusetts General Hospital, Harris Orthopaedic Laboratory
12. Harvard Medical School, Department of Orthopaedic Surgery
Background and purpose 
Nordic Arthroplasty Register Association (NARA) 
was established in 2007 by Sweden, Norway and 
Denmark with the overall aim to improve the quality 
of joint replacement surgery by register research col-
laboration. Finland became member of NARA in 
2010. Total population of the 4 countries is currently 
26 million. It has been stated based on NARA data 
that the survival of cemented implants for total hip re-
placement is higher than that of uncemented implants 
in patients aged 65 years or older (1). In younger pa-
tients, uncemented implants do not perform better 
with regard to overall revision rate, but have a lower 
long-term risk of revision due to aseptic loosening (2). 
According to previous Nordic Arthroplasty Register 
Association (NARA) data 10-year  implant survival of 
cemented total hip arthroplasty (THA) is 94 % and 
96 % in patients aged 65 to 74 and 75 or older, re-
spectively. We now report brand-level comparison of 
cemented THA based on the NARA database which 
has not been assessed previously.
Patients and methods
There were 360,584 primary all-cemented THAs reg-
istered in the NARA database from 1995 to 2013. 
Implant survival of the 9 most common cemented 
THA was assessed: Lubinus, Exeter, Charnley, Spec-
tron , MS 30, CPT, Elite, Müller THA, and C-stem 
THA. The versions of the study implants were not 
necessarily the same in the 4 countries. Further, the 
study devices were not necessarily coded similarly in 
the 4 registers. Only those cup/stem combinations 
were included with at least 100 implantations in a 
country. We used Kaplan-Meier analysis with 95 % 
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confidence interval (CI) to study implant survival at 
10 and 15 years, and Cox multiple regression model 
to assess survival and hazard ratio (HR) with revision 
for any revision as endpoint, with confidence interval 
(CI), and with adjustments for age, sex, diagnosis, and 
femoral head material. 
Results
Spectron EF ((89.9 % (CI: 89.3-90.5)) and Elite THA 
((89.8 % (CI: 89.0-90.6)) had the lowest 10-year sur-
vivorship.  Lubinus ((95.7 % (CI: 95.5-95.9)), MS 30 
((96.6 % (CI: 95.8-97.4)), and C-stem THA ((95.8 
% (CI: 94.8-96.8) had a 10-year survivorship of 95 % 
or over. Lubinus ((RR 0.77 (CI: 0.73-0.81)), Müller 
((RR 0.83 (CI: 0.70-0.99)), MS-30 ((RR 0.73 (CI: 
0.63-0.86)), C-stem ((RR 0.70 (CI: 0.55-0.90)), and 
Exeter Duration THA ((RR 0.84 (CI: 0.77-0.90)) had 
a decreased revision risk compared to Charnley THA, 
the reference implant.
Interpretation 
Spectron EF and Elite THA had a decreased implant 
survival compared to the Charnley THA, the ref-
erence implant. Implant survival of Müller, MS 30, 
CPT, and C-stem THA (94.9 to 96.6 % at 10 years) 
was far above an acceptable limit for 10 year surviv-
al. However, total amount of these devices was small 
compared to Charnley, Lubinus and Exeter THA, 
although all had been implanted in over 2000 hips. 
When an implant becomes more common and is used 
by an increasing amount of surgeons the results will 
be more representative since they can be supposed to 
mirror a wider variation of differences in surgical tech-
nique.
A major strength of our study is the unique col-
laboration of 4 national registries to create a multi-
national database with large numbers of patients and 
a long follow-up time. The main weakness of our 
study is that we were not able to assess every updated 
version of each device separately. The study devices 
were implant families consisting of several versions of 
the device. Another weakness is that we were not able 
to assess cup and stem survival separately with revision 
for any reason as the end point.
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